{"id":33422,"date":"2025-09-19T17:28:00","date_gmt":"2025-09-19T11:58:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33422"},"modified":"2025-09-19T15:19:25","modified_gmt":"2025-09-19T09:49:25","slug":"alcohol-use-disorder-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape","title":{"rendered":"Alcohol Use Disorder: A High-Burden Disease with Untapped Market Promise"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e73bf287497\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e73bf287497\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape\/#Insights_around_AUD_patient_burden\" >Insights around AUD patient burden<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape\/#The_AUD_Treatment_Journey\" >The AUD Treatment Journey<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape\/#Factors_responsible_for_a_massive_gap_in_existing_AUD_treatment_rates\" >Factors responsible for a massive gap in existing AUD treatment rates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape\/#Upcoming_AUD_competitive_landscape_Will_they_accelerate_the_treatment_rate\" >Upcoming AUD competitive landscape: Will they accelerate the treatment rate?<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-insights-around-aud-patient-burden\"><span class=\"ez-toc-section\" id=\"Insights_around_AUD_patient_burden\"><\/span><strong>Insights around AUD patient burden<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Over the years, AUD has emerged as a pressing global health challenge, with prevalence steadily rising, particularly in the United States and parts of Europe. This upward trend is fueled by modern lifestyle pressures, work-related stress, anxiety, and shifting social habits, as well as increased exposure to medications that may contribute to dependency.<\/p>\n\n\n\n<p>Prevalence patterns vary widely across regions. In Asian countries, including Japan, relatively low rates of AUD are attributed to cultural norms and generally lower alcohol consumption per capita.<\/p>\n\n\n\n<p>In contrast, the United States exhibits a markedly higher prevalence, with recent estimates suggesting <strong>~28 million<\/strong> Americans are affected by AUD due to more permissive cultural attitudes toward drinking, where the majority of them fall above the age of 30 years.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/alcohol-use-disorder-market\"><img decoding=\"async\" width=\"1024\" height=\"408\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151618\/Alcohol-Use-Disorder-Epidemiological-Trends-1024x408.webp\" alt=\"Alcohol-Use-Disorder-Epidemiological-Trends\" class=\"wp-image-33427\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151618\/Alcohol-Use-Disorder-Epidemiological-Trends-1024x408.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151618\/Alcohol-Use-Disorder-Epidemiological-Trends-300x120.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151618\/Alcohol-Use-Disorder-Epidemiological-Trends-150x60.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151618\/Alcohol-Use-Disorder-Epidemiological-Trends-768x306.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151618\/Alcohol-Use-Disorder-Epidemiological-Trends-1536x612.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151618\/Alcohol-Use-Disorder-Epidemiological-Trends.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>According to Delveinsight\u2019s estimates, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alcohol-use-disorder-epidemiology-forecast\">12-month diagnosed prevalent cases of AUD<\/a> in the 7MM were <strong>36.8 million<\/strong> in 2024. Variations in severity were observed within the 7MM, with mild AUD patients contributing the most in the US and severe cases leading in Japan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-aud-treatment-journey\"><span class=\"ez-toc-section\" id=\"The_AUD_Treatment_Journey\"><\/span><strong>The AUD Treatment Journey<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/alcohol-use-disorder-market\">treatment journey for AUD<\/a> spans over seven decades, beginning in 1951 with the FDA approval of ANTABUSE (disulfiram).. In 1994, a new chapter unfolded with <strong>REVIA <\/strong>(oral naltrexone) in the US, which shifted the focus from deterrence to reducing cravings and relapse risk by targeting opioid receptors. To improve adherence further, <strong>VIVITROL<\/strong>, an extended-release injectable naltrexone, was launched in 2006 in the US, offering more extended coverage but limited by liver safety concerns, a common comorbidity in AUD. <strong>CAMPRAL <\/strong>(acamprosate) was introduced in 2004, providing neuroprotective support for maintaining abstinence in already sober patients. While its branded presence has faded, generic versions remain widely prescribed due to their tolerability.&nbsp;<\/p>\n\n\n\n<p>Parallel to these developments, in Europe and Japan, the market evolved differently with <strong>SELINCRO <\/strong>(nalmefene), approved to reduce alcohol consumption without requiring prior detoxification. Meanwhile, France approved <strong>BACLOCUR <\/strong>(baclofen) after long off-label use, and sodium oxybate (GHB) gained traction in Italy and Austria for withdrawal and abstinence management.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/alcohol-use-disorder-market\"><img decoding=\"async\" width=\"1024\" height=\"351\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151640\/Marketed-Drugs-Approval-Milestones-1024x351.webp\" alt=\"Marketed-Drugs-Approval-Milestones\" class=\"wp-image-33428\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151640\/Marketed-Drugs-Approval-Milestones-1024x351.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151640\/Marketed-Drugs-Approval-Milestones-300x103.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151640\/Marketed-Drugs-Approval-Milestones-150x51.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151640\/Marketed-Drugs-Approval-Milestones-768x264.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151640\/Marketed-Drugs-Approval-Milestones-1536x527.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151640\/Marketed-Drugs-Approval-Milestones.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Alongside branded AUD drugs, off-label generics such as topiramate, gabapentin, ondansetron, and benzodiazepines etc., have become widely used because of cost-effectiveness and clinician familiarity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-factors-responsible-for-a-massive-gap-in-existing-aud-treatment-rates\"><span class=\"ez-toc-section\" id=\"Factors_responsible_for_a_massive_gap_in_existing_AUD_treatment_rates\"><\/span><strong>Factors responsible for a massive gap in existing AUD treatment rates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Despite the high prevalence, why are only 5-10% of the diagnosed patients getting treated?. Several factors contribute to this gap.&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Stigma and fear of being labeled often discourage individuals from seeking help. Lack of awareness about AUD as a medical condition is another reason.<\/li>\n\n\n\n<li>Limited access to specialized services, especially in low-resource settings, and financial barriers.\u00a0<\/li>\n\n\n\n<li>In addition, many patients show reluctance or denial due to social pressure.<\/li>\n<\/ul>\n\n\n\n<p>Currently, the AUD market is entering a new phase. With generics dominating current use, the focus is shifting toward emerging therapies designed to be more tailored, accessible, and patient-friendly.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-upcoming-aud-competitive-landscape-will-they-accelerate-the-treatment-rate\"><span class=\"ez-toc-section\" id=\"Upcoming_AUD_competitive_landscape_Will_they_accelerate_the_treatment_rate\"><\/span><strong>Upcoming AUD competitive landscape: Will they accelerate the treatment rate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Adherence to the FDA-approved medications remains a significant challenge, often limiting their real-world effectiveness. Factors such as side effects, dosing frequency, and the stigma around taking daily medications contribute to poor compliance.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/alcohol-use-disorder-market\"><img decoding=\"async\" width=\"1024\" height=\"532\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151704\/Glimpse-of-upcoming-competitors-in-the-AUD-market-1024x532.webp\" alt=\"Glimpse-of-upcoming-competitors-in-the-AUD-market\" class=\"wp-image-33429\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151704\/Glimpse-of-upcoming-competitors-in-the-AUD-market-1024x532.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151704\/Glimpse-of-upcoming-competitors-in-the-AUD-market-300x156.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151704\/Glimpse-of-upcoming-competitors-in-the-AUD-market-150x78.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151704\/Glimpse-of-upcoming-competitors-in-the-AUD-market-768x399.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151704\/Glimpse-of-upcoming-competitors-in-the-AUD-market-1536x798.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151704\/Glimpse-of-upcoming-competitors-in-the-AUD-market.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>To address these issues, various alternative routes of administration are being actively developed. <a href=\"https:\/\/www.delveinsight.com\/report-store\/alcohol-use-disorder-pipeline-insight\">Emerging AUD therapies<\/a> are exploring varying routes of administration, including <strong>intranasal <\/strong>(BPL-003 by Beckley Psytech and Atai Life Sciences), <strong>subcutaneous <\/strong>(Pemvidutide by Altimmune), and <strong>oral <\/strong>(AD04 by Adial Pharmaceuticals), aiming to improve adherence and treatment outcomes. Among these, AD04 is anticipated to launch by 2027 in the US with an estimated cost of therapy of roughly <strong>USD 5,000<\/strong> at the time of launch, which stands out with promising safety and efficacy, with a strong commercial potential. These novel delivery methods aim to improve patient adherence by reducing the treatment burden, ensuring more consistent therapeutic levels, and offering discreet options that help overcome stigma and forgetfulness.<\/p>\n\n\n\n<p>Beyond administration, another critical gap lies in the lack of severity-specific AUD treatments. Currently, no approved treatment is tailored to AUD severity; patients generally receive uniform therapy regardless of individual risk. However, <a href=\"https:\/\/www.delveinsight.com\/report-store\/alcohol-use-disorder-pipeline-insight\">emerging AUD drugs<\/a> like <strong>BPL-003, Sunobinop, TMP-301\/HTL0014242, Pemvidutide<\/strong>, and others are being evaluated for moderate-to-severe AUD, with BPL-003 expected to launch by 2028.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/alcohol-use-disorder-market\"><img decoding=\"async\" width=\"1024\" height=\"547\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151727\/Estimated-Revenue-generated-by-therapies-in-2034-in-the-7MM-1024x547.webp\" alt=\"Estimated-Revenue-generated-by-therapies-in-2034-in-the-7MM\" class=\"wp-image-33430\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151727\/Estimated-Revenue-generated-by-therapies-in-2034-in-the-7MM-1024x547.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151727\/Estimated-Revenue-generated-by-therapies-in-2034-in-the-7MM-300x160.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151727\/Estimated-Revenue-generated-by-therapies-in-2034-in-the-7MM-150x80.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151727\/Estimated-Revenue-generated-by-therapies-in-2034-in-the-7MM-768x410.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151727\/Estimated-Revenue-generated-by-therapies-in-2034-in-the-7MM-1536x821.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151727\/Estimated-Revenue-generated-by-therapies-in-2034-in-the-7MM.webp 1920w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Despite the high prevalence of alcohol dependence, treatment rates remain disproportionately low, highlighting a persistent public health challenge. Psychosocial interventions, including cognitive behavioral therapy and relapse prevention strategies, are significantly underutilized, underscoring a critical gap in delivering comprehensive, holistic care for AUD. Compounding this issue, the limited efficacy, accessibility, and uptake of approved pharmacological treatments such as naltrexone, acamprosate, and disulfiram have led clinicians to explore alternative strategies. As a result, off-label agents like gabapentin, topiramate, and baclofen have gained increasing traction in clinical practice, despite lacking formal regulatory approval for AUD.<\/p>\n\n\n\n<p>In 2020, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alcohol-use-disorder-market\">AUD treatment market<\/a> across seven major markets was approximately <strong>USD\u202f900 million<\/strong>, with the US alone accounting for about <strong>USD\u202f800 million<\/strong>, with over <strong>80%<\/strong> of the total share. The anticipated launch of novel therapies, including <strong>AD04, BPL-003, MN-166, Sunobinop, and TMP-301<\/strong>, is expected to expand AUD treatment options and stimulate market growth. As innovative therapies enter the market, the focus must remain on integrating pharmacological and psychosocial approaches to address the full complexity of alcohol use disorder.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/alcohol-use-disorder-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151546\/Alcohol-Use-Disorder-Market-Assessment-1024x194.webp\" alt=\"Alcohol Use Disorder Market Assessment\" class=\"wp-image-33426\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151546\/Alcohol-Use-Disorder-Market-Assessment-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151546\/Alcohol-Use-Disorder-Market-Assessment-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151546\/Alcohol-Use-Disorder-Market-Assessment-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151546\/Alcohol-Use-Disorder-Market-Assessment-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151546\/Alcohol-Use-Disorder-Market-Assessment-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151546\/Alcohol-Use-Disorder-Market-Assessment.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Insights around AUD patient burden Over the years, AUD has emerged as a pressing global health challenge, with prevalence steadily rising, particularly in the United States and parts of Europe. This upward trend is fueled by modern lifestyle pressures, work-related stress, anxiety, and shifting social habits, as well as increased exposure to medications that may [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":33424,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16820,19749,19753,19750,19752,19751],"industry":[17225],"therapeutic_areas":[17278],"class_list":["post-33422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-alcohol-use-disorder","tag-alcohol-use-disorder-aud","tag-alcohol-use-disorder-clinical-trials","tag-alcohol-use-disorder-market","tag-alcohol-use-disorder-pipeline-insights","tag-alcohol-use-disorder-therapies","industry-pharmaceutical","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Alcohol Use Disorder: Treatment Gaps and Pipeline Potential<\/title>\n<meta name=\"description\" content=\"In 2020, the alcohol use disorder treatment market across seven major markets was approximately USD\u202f900 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alcohol Use Disorder: Treatment Gaps and Pipeline Potential\" \/>\n<meta property=\"og:description\" content=\"In 2020, the alcohol use disorder treatment market across seven major markets was approximately USD\u202f900 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-19T11:58:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151435\/alcohol-use-disorder-treatment-landscape.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alcohol Use Disorder: Treatment Gaps and Pipeline Potential","description":"In 2020, the alcohol use disorder treatment market across seven major markets was approximately USD\u202f900 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Alcohol Use Disorder: Treatment Gaps and Pipeline Potential","og_description":"In 2020, the alcohol use disorder treatment market across seven major markets was approximately USD\u202f900 million.","og_url":"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-09-19T11:58:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151435\/alcohol-use-disorder-treatment-landscape.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape","name":"Alcohol Use Disorder: Treatment Gaps and Pipeline Potential","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151435\/alcohol-use-disorder-treatment-landscape.webp","datePublished":"2025-09-19T11:58:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"In 2020, the alcohol use disorder treatment market across seven major markets was approximately USD\u202f900 million.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/alcohol-use-disorder-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151435\/alcohol-use-disorder-treatment-landscape.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151435\/alcohol-use-disorder-treatment-landscape.webp","width":466,"height":284,"caption":"alcohol-use-disorder-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/19151435\/alcohol-use-disorder-treatment-landscape-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alcohol Use Disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alcohol Use Disorder (AUD)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alcohol Use Disorder Clinical Trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alcohol Use Disorder Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alcohol Use Disorder Pipeline Insights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alcohol Use Disorder Therapies<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alcohol Use Disorder<\/span>","<span class=\"advgb-post-tax-term\">Alcohol Use Disorder (AUD)<\/span>","<span class=\"advgb-post-tax-term\">Alcohol Use Disorder Clinical Trials<\/span>","<span class=\"advgb-post-tax-term\">Alcohol Use Disorder Market<\/span>","<span class=\"advgb-post-tax-term\">Alcohol Use Disorder Pipeline Insights<\/span>","<span class=\"advgb-post-tax-term\">Alcohol Use Disorder Therapies<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 months ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Sep 19, 2025","modified":"Updated on Sep 19, 2025"},"absolute_dates_time":{"created":"Posted on Sep 19, 2025 5:28 pm","modified":"Updated on Sep 19, 2025 3:19 pm"},"featured_img_caption":"alcohol-use-disorder-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33422"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33422\/revisions"}],"predecessor-version":[{"id":33431,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33422\/revisions\/33431"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33424"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33422"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33422"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}